ACIU Quote, Financials, Valuation and Earnings

CRISPR Therapeutics AG has a net margin of -1688.87% compared to AC Immune SA's net margin of -11973.12%. AC Immune SA's return on equity of -75.88% beat CRISPR Therapeutics AG's return on equity of -26.17%.

AC Immune SA has a consensus price target of $9.61, signalling upside risk potential of 235.06%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 45.26%. Given that AC Immune SA has higher upside potential than CRISPR Therapeutics AG, analysts believe AC Immune SA is more attractive than CRISPR Therapeutics AG.

AC Immune SA has a beta of 1.602, which suggesting that the stock is 60.243% more volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.

AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

AC Immune SA quarterly revenues are $1.2M, which are larger than CRISPR Therapeutics AG quarterly revenues of $889K. AC Immune SA's net income of -$19.8M is higher than CRISPR Therapeutics AG's net income of -$106.4M. Notably, AC Immune SA's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is 56.16x versus 127.71x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

Molecular Partners AG has a net margin of -1688.87% compared to AC Immune SA's net margin of -2408.81%. AC Immune SA's return on equity of -75.88% beat Molecular Partners AG's return on equity of -49.28%.

AC Immune SA has a consensus price target of $9.61, signalling upside risk potential of 235.06%. On the other hand Molecular Partners AG has an analysts' consensus of $10.72 which suggests that it could grow by 140.81%. Given that AC Immune SA has higher upside potential than Molecular Partners AG, analysts believe AC Immune SA is more attractive than Molecular Partners AG.

AC Immune SA has a beta of 1.602, which suggesting that the stock is 60.243% more volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend.

AC Immune SA quarterly revenues are $1.2M, which are larger than Molecular Partners AG quarterly revenues of --. AC Immune SA's net income of -$19.8M is lower than Molecular Partners AG's net income of -$14.8M. Notably, AC Immune SA's price-to-earnings ratio is -- while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is 56.16x versus 187.52x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines Ltd. has a net margin of -1688.87% compared to AC Immune SA's net margin of 8.84%. AC Immune SA's return on equity of -75.88% beat BeOne Medicines Ltd.'s return on equity of 1.92%.

AC Immune SA has a consensus price target of $9.61, signalling upside risk potential of 235.06%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $401.52 which suggests that it could grow by 18.84%. Given that AC Immune SA has higher upside potential than BeOne Medicines Ltd., analysts believe AC Immune SA is more attractive than BeOne Medicines Ltd..

AC Immune SA has a beta of 1.602, which suggesting that the stock is 60.243% more volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.

AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.

AC Immune SA quarterly revenues are $1.2M, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. AC Immune SA's net income of -$19.8M is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, AC Immune SA's price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 650.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is 56.16x versus 7.55x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.